CAPITAL STOCK (AS RESTATED) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CAPITAL STOCK (AS RESTATED) | NOTE 13 - CAPITAL STOCK (AS RESTATED)
Common Stock
Capital Contributions
During the nine months ended September 30, 2025 the Company’s controlling shareholder, Abundia Financial made capital contributions of $941,376 , these cash contributions were made to support the working capital need of the Company and were made prior to the completion of the Share Exchange.
In connection with the reverse acquisition described in Note 6 – ACQUISITION, the Company incurred a success fee of $12.4 million. This fee was paid by Abundia Financial using shares of the Company’s common stock that Abundia Financial owned and is therefore treated as a capital contribution.
ELOC Agreement
On July 10, 2025, the Company entered into the ELOC Agreement with an institutional investor (“ELOC Investor”), providing for a 24-month committed equity financing facility, pursuant to which the ELOC Investor has committed to purchase, at the Company’s direction in its sole discretion, up to an aggregate of $ of Common Stock, subject to certain limitations set forth in the ELOC Agreement (the “Purchase Shares”).
The purchase price per share is equal to 96% of the lowest daily volume-weighted average price (“VWAP”) during a specified measurement period following each purchase notice. The Company may issue up to shares of Common Stock (exclusive of the commitment shares issued pursuant to the ELOC agreement described below) under the ELOC, subject to a(i) 9.99% beneficial ownership cap, and (ii) a 19.99% exchange cap, unless shareholder approval is obtained or sales are made at or above the minimum price as defined by NYSE American rules.
As consideration for the ELOC investors commitment, the Company agreed to issue a total of shares of Common Stock as a commitment fee, consisting of shares of Common Stock issued at closing and shares of Common Stock issued upon the effectiveness of the registration statement registering all shares of Common Stock issuable pursuant to the ELOC (the “Commitment Shares”). The value of these shares at the time of issue was $3,342,000, this amount has been recognized in the income statement for the three and nine months ended September 30, 2025. The Company also entered into a registration rights agreement requiring it to file and maintain an effective resale registration statement for such shares issued under the ELOC.
The ELOC Agreement may be terminated by the Company at any time after commencement, provided the commitment fee and legal fees have been paid. The agreement automatically terminates upon the earlier of (i) full drawdown, (ii) expiration of the 24-month term, (iii) delisting, or (iv) bankruptcy events.
During the three and nine months ended September 30, 2025, the Company issued shares of Common Stock under the ELOC Agreement, for total gross proceeds of $1,638,361.
The Company engaged Univest Securities LLC as placement agent and agreed to pay a cash fee equal to 1.5% of the gross funding amount for each drawdown.
Stock Based Compensation
Share awards
Effective June 27, 2025, the HUSA Board of Directors approved the issuance of shares of common stock to the legacy executive officers, directors and employees of HUSA, subject to shareholder approval. Effective September 8, 2025, the share issuance was approved by written consent of the Company’s controlling shareholder and the Company recognized stock compensation of $based the Company closing share price of $ at the date of approval. These shares were issued in January 2026.
Restricted Stock / Option Awards
Effective August 1, 2025, the Board authorized the issuance of $80,000 of restricted stock or options awards to 4 directors as part of their annual compensation and a further $60,000 of restricted stock or options awards to 2 of these 4 directors as a signing on fee. The restricted stock or options awards were to vest over a 12-month period and were subject to the approval of the Company’s Long-Term Incentive Plan (“LTIP”). As the approval of the LTIP by the Company’s controlling shareholder was considered to be perfunctory, the Company began recognizing the compensation expense associated with these awards over their 12-month vesting period on a straight-line basis commencing August 1, 2025. As of September 30, 2025, stock compensation of $ had been recognized in respect of these restricted stock or options awards and there was a balance of $unvested stock compensation to be recognized through July 31, 2026.
Warrants
Bridge Loan Warrants
As part of the Share Exchange, the Company acquired a number of warrants that had been issued in conjunction with a bridge loan in HUSA. The Bridge Loan Warrants are exercisable, for a period of ten years, expiring September 18, 2029, to purchase an aggregate of shares of common stock of the Company.
A summary of warrant activity and related information for 2025 is presented below:
On June 6, 2025. the Company effected a 1-for-10 reverse stock split (the “Reverse Stock Split”) of all outstanding shares of its common stock, $ par value per share (“Common Stock”). The number of warrants outstanding has been adjusted to reflect this stock split.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||